Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
IONS

IONS - Ionis Pharmaceuticals Inc Stock Price, Fair Value and News

47.84USD+0.51 (+1.08%)Market Closed

Market Summary

IONS
USD47.84+0.51
Market Closed
1.08%

IONS Alerts

  • 2 major insider sales recently.

IONS Stock Price

View Fullscreen

IONS RSI Chart

IONS Valuation

Market Cap

7.0B

Price/Earnings (Trailing)

-18.15

Price/Sales (Trailing)

8.99

EV/EBITDA

-21.27

Price/Free Cashflow

-20.46

IONS Price/Sales (Trailing)

IONS Profitability

EBT Margin

-46.84%

Return on Equity

-129.76%

Return on Assets

-13.92%

Free Cashflow Yield

-4.89%

IONS Fundamentals

IONS Revenue

Revenue (TTM)

776.6M

Rev. Growth (Yr)

-8.45%

Rev. Growth (Qtr)

-63.18%

IONS Earnings

Earnings (TTM)

-384.8M

Earnings Growth (Yr)

-14.86%

Earnings Growth (Qtr)

-1.4K%

Breaking Down IONS Revenue

Last 7 days

-0.3%

Last 30 days

17.7%

Last 90 days

17.6%

Trailing 12 Months

16.8%

How does IONS drawdown profile look like?

IONS Financial Health

Current Ratio

7.37

Debt/Equity

1.9

Debt/Cashflow

-0.57

IONS Investor Care

Shares Dilution (1Y)

2.01%

Diluted EPS (TTM)

-2.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024776.6M000
2023576.0M630.6M615.0M787.6M
2022840.8M848.8M875.5M587.4M
2021707.5M687.7M660.7M810.5M
2020958.8M940.5M932.7M729.3M
2019752.5M798.5M821.0M1.1B
2018547.3M552.8M579.9M599.7M
2017425.5M499.3M506.7M518.7M
2016258.0M176.0M237.8M346.6M
2015248.6M257.4M274.9M283.7M
2014132.1M151.1M171.5M214.2M
2013122.2M112.9M124.9M147.3M
2012101.2M123.7M114.6M102.0M
201199.7M101.0M93.1M99.1M
2010120.0M112.5M114.3M108.5M
20090112.0M116.8M121.6M
2008000107.2M

Tracking the Latest Insider Buys and Sells of Ionis Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 16, 2024
klein joseph iii
sold
-600,000
50.00
-12,000
-
Jul 16, 2024
diaz allene m.
sold
-81,019
49.4926
-1,637
-
Jul 16, 2024
klein joseph iii
acquired
293,040
24.42
12,000
-
Jul 15, 2024
herman joan e
acquired
-
-
4,677
-
Jul 15, 2024
diaz allene m.
acquired
-
-
4,677
-
Jul 15, 2024
parshall b lynne
acquired
-
-
4,677
-
Jul 15, 2024
loscalzo joseph
acquired
-
-
4,677
-
Jul 15, 2024
wender joseph h
acquired
-
-
4,677
-
Jul 15, 2024
berthelsen spencer r
acquired
-
-
4,677
-
Jun 17, 2024
berthelsen spencer r
acquired
568,480
35.53
16,000
-

1–10 of 50

Which funds bought or sold IONS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
Sumitomo Mitsui Trust Holdings, Inc.
reduced
-9.55
-52,965
9,495,350
0.01%
Jul 19, 2024
RAYMOND JAMES & ASSOCIATES
reduced
-79.06
-3,755,720
1,123,490
-%
Jul 19, 2024
China Universal Asset Management Co., Ltd.
reduced
-38.81
-397,601
817,369
0.12%
Jul 19, 2024
First Pacific Financial
sold off
-100
-1,258
-
-%
Jul 19, 2024
Raymond James Financial Services Advisors, Inc.
added
13.53
145,294
730,866
-%
Jul 18, 2024
Blue Trust, Inc.
new
-
4,638
4,638
-%
Jul 18, 2024
Assenagon Asset Management S.A.
reduced
-91.07
-10,604,600
1,154,610
-%
Jul 17, 2024
LifeSteps Financial, Inc.
sold off
-100
-8,670
-
-%
Jul 17, 2024
KBC Group NV
added
7.76
26,000
162,000
-%
Jul 17, 2024
Kelly Financial Services LLC
unchanged
-
-217
1,301
-%

1–10 of 43

Are Funds Buying or Selling IONS?

Are funds buying IONS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IONS
No. of Funds

Unveiling Ionis Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
t. rowe price investment management, inc.
9.2%
13,201,453
SC 13G
Feb 13, 2024
bb biotech ag
6.0%
8,590,000
SC 13G/A
Feb 13, 2024
vanguard group inc
9.90%
14,203,481
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 26, 2024
blackrock inc.
6.3%
9,057,282
SC 13G/A
Jun 09, 2023
vanguard group inc
10.07%
14,414,917
SC 13G/A
Feb 14, 2023
t. rowe price investment management, inc.
8.2%
11,678,259
SC 13G
Feb 14, 2023
bb biotech ag
6.8%
9,635,000
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.54%
13,546,694
SC 13G/A

Recent SEC filings of Ionis Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jul 17, 2024
4
Insider Trading
Jul 17, 2024
4
Insider Trading
Jul 17, 2024
4
Insider Trading
Jul 17, 2024
4
Insider Trading
Jul 17, 2024
4
Insider Trading
Jul 17, 2024
4
Insider Trading
Jul 17, 2024
4
Insider Trading
Jul 16, 2024
144
Notice of Insider Sale Intent
Jul 16, 2024
144
Notice of Insider Sale Intent
Jul 03, 2024
4
Insider Trading

Peers (Alternatives to Ionis Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Ionis Pharmaceuticals Inc News

Latest updates
American Banking and Market News21 hours ago
Defense World18 Jul 202408:56 am

Ionis Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-63.2%119,497,000324,505,000144,207,000188,411,000130,524,000151,889,500159,767,000133,791,000141,919,000440,006,000133,093,000125,750,000111,607,000290,281,000160,079,000145,537,000133,367,000493,680,500167,892,000163,813,000297,214,000
Costs and Expenses-18.6%269,010,000330,627,000287,472,000278,606,000244,672,000359,909,000218,921,000219,305,000199,423,000219,403,000218,942,000198,719,000203,578,000312,945,000196,616,000197,291,000194,494,000233,028,000165,369,000182,640,000175,679,000
  S&GA Expenses-25.9%52,644,00071,010,50069,951,00046,142,00045,516,00047,950,00034,416,00033,802,00034,127,00037,600,00031,093,00056,455,00061,199,000138,866,50068,447,00072,015,00074,994,00083,276,00060,036,00075,111,00068,221,000
EBITDA Margin-10.3%-0.44-0.39-0.58-0.41-0.50-0.400.040.000.02-0.01-0.37-0.28---------
Interest Expenses-8.9%4,151,0004,558,0004,203,0002,291,0001,608,0001,731,0002,139,0002,130,0002,122,0002,238,0002,340,0002,357,0002,414,0002,434,0002,428,0002,441,0002,207,000-22,963,50012,002,00011,802,00011,599,000
Income Taxes-98.5%100,0006,531,0006,600,0007,800,00011,380,0008,107,000300,0002,260,0001,100,000297,500-1,300,000327,000130,000341,114,5005,064,0002,084,000-3,072,00042,318,500-14,900,000-6,927,00031,000,000
Earnings Before Taxes-5059.2%-142,728,000-2,766,500-140,808,000-77,448,000-112,943,000-44,330,000-46,709,000-102,875,000-64,071,000224,914,000-83,773,000-80,548,000-89,739,000-14,572,500-31,550,000-35,476,000-52,954,000230,257,5003,517,000-16,939,000121,931,000
EBT Margin-10.5%-0.47-0.42-0.61-0.45-0.53-0.440.01-0.030.00-0.04-0.41-0.31---------
Net Income-1441.6%-142,803,000-9,263,000-147,410,000-85,290,000-124,323,000-52,430,000-46,992,000-105,135,000-65,165,000224,613,000-82,466,000-80,875,000-89,869,000-85,987,000-24,467,000-25,636,000-39,628,000184,415,00026,163,000-876,00084,443,000
Net Income Margin-6.5%-0.50-0.47-0.67-0.49-0.57-0.460.01-0.030.00-0.04-0.51-0.46---------
Free Cashflow-558.5%-154,431,00033,684,000-111,163,000-109,375,000-144,464,000-204,334,000-29,971,000-21,431,000-34,355,000201,185,000-58,897,000-67,010,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-7.6%2,7642,9902,9342,9712,8852,5342,4222,4562,5192,6122,4152,4972,2492,3903,0963,0793,0913,2332,8952,8782,836
  Current Assets-8.6%2,4162,6422,5852,6172,5432,2032,1522,1912,2532,3452,1562,2381,9892,1312,5372,5312,5582,7212,4082,4142,374
    Cash Equivalents-12.6%349399352425309276315522543869633565414398633530486683248273376
  Inventory6.5%30.0028.0026.0026.0022.0022.0021.0020.0024.0025.0023.0024.0022.0022.0022.0024.0023.0018.0019.0019.0011.00
  Net PPE2.5%73.0071.0071.0092.0085.0074.00181177178178180179180181182173164154149135134
Liabilities-5.2%2,4672,6032,6192,5432,3991,9611,8281,8311,8101,8401,8841,9141,5681,6461,4891,4841,5211,5491,3971,4211,448
  Current Liabilities-26.9%328448404288259312283268228241280294295599245231258273232241252
  Long Term Debt-10.0%563625562114545-621621543619542617541-289284280275596587577
    LT Debt, Current0.1%44.0044.00--------62.0062.0062.00309-------
    LT Debt, Non Current-10.0%563625562114545-621621543619542617541-289284280275596587577
Shareholder's Equity-23.3%2973873154284875735946257107725315836817431,5211,5031,4721,5771,4981,4571,387
  Retained Earnings-8.0%-1,938-1,795-1,786-1,639-1,553-1,429-1,377-1,330-1,225-1,159-1,384-1,302-1,221-1,131-909-878-846-707-857-883-882
  Additional Paid-In Capital2.5%2,2702,2152,1482,1182,0892,0602,0352,0091,9831,9641,9421,9101,9261,8962,3122,2722,2342,2042,2192,1772,118
Shares Outstanding1.0%146144143143143142142142142141141141---------
Minority Interest---------------223218210213162188180
Float----4,243---3,805---4,675---6,748---7,483-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-556.2%-149,93832,865-109,022-97,364-133,992-200,195-24,429-18,096-31,650203,687-55,574-62,652-54,66297,977-10,275-44,218-7,592277,839-12,806-27,111107,705
  Share Based Compensation19.0%31,34026,33625,96326,56226,94825,68923,83724,50226,23622,25930,53730,02137,86195,04045,84448,44340,79035,01024,12741,93245,505
Cashflow From Investing384.9%76,105-26,71368,71169,515-325,640212,147-183,930-3,304-287,54995,109121,971-101,03078,856187,849101,94079,695-95,007138,1911,396-110,687-70,174
Cashflow From Financing-42.1%23,57040,724-32,267143,538492,087-51,0191,8341,215-7,325-62,4901,458314,542-7,577-521,48010,9378,435-94,50119,225-13,17434,51059,460
  Buy Backs----------------48.0090,50034,400---
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

IONS Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Revenue$ 119,497$ 130,524
Expenses:  
Cost of sales2,1511,343
Research, development and patent214,215197,813
Selling, general and administrative52,64445,516
Total operating expenses269,010244,672
Loss from operations(149,513)(114,148)
Other income (expense):  
Investment income26,28518,627
Interest expense(4,151)(1,608)
Interest expense related to sale of future royalties(17,959)(15,515)
Gain (loss) on investments2,333(529)
Other income277230
Loss before income tax expense(142,728)(112,943)
Income tax expense(75)(11,380)
Net loss$ (142,803)$ (124,323)
Basic net loss per share (in dollars per share)$ (0.98)$ (0.87)
Diluted net loss per share (in dollars per share)$ (0.98)$ (0.87)
Shares used in computing basic net loss per share (in shares)145,538142,735
Shares used in computing diluted net loss per share (in shares)145,538142,735
Commercial Revenue [Member]  
Revenue:  
Revenue$ 59,593$ 67,768
SPINRAZA Royalties [Member]  
Revenue:  
Revenue38,45550,247
WAINUA Royalties [Member]  
Revenue:  
Revenue1,1250
Other Commercial Revenue [Member]  
Revenue:  
Revenue20,01317,521
Research and Development Revenue [Member]  
Revenue:  
Revenue59,90462,756
Collaborative Agreement Revenue [Member]  
Revenue:  
Revenue49,34538,334
WAINUA Joint Development Revenue [Member]  
Revenue:  
Revenue$ 10,559$ 24,422

IONS Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 348,889$ 399,266
Short-term investments1,857,3271,931,935
Contracts receivable5,14097,778
Inventories30,25928,425
Other current assets174,060184,449
Total current assets2,415,6752,641,853
Property, plant and equipment, net72,79571,043
Right-of-use assets169,431171,896
Deposits and other assets106,027105,280
Total assets2,763,9282,990,072
Current liabilities:  
Accounts payable13,08226,027
Accrued compensation21,53767,727
Accrued liabilities106,048147,894
Income taxes payable2,2102,151
0.125 percent convertible senior notes, net44,37744,332
Current portion of deferred contract revenue130,406151,128
Other current liabilities9,9888,831
Total current liabilities327,648448,090
Long-term deferred contract revenue215,088241,184
Liability related to sale of future royalties, net525,072513,736
Long-term lease liabilities168,674170,875
Long-term obligations41,80041,836
Total liabilities2,467,4132,603,386
Stockholders' equity:  
Common stock, $0.001 par value; 300,000,000 shares authorized, 145,844,719 and 144,340,526 shares issued and outstanding at March 31, 2024 (unaudited) and December 31, 2023, respectively146144
Additional paid-in capital2,270,0472,215,098
Accumulated other comprehensive loss(34,964)(32,645)
Accumulated deficit(1,938,714)(1,795,911)
Total stockholders' equity296,515386,686
Total liabilities and stockholders' equity2,763,9282,990,072
1.75 Percent Convertible Senior Notes [Member]  
Current liabilities:  
Convertible senior notes, net562,964562,285
0 Percent Convertible Senior Notes [Member]  
Current liabilities:  
Convertible senior notes, net$ 626,167$ 625,380
IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.
 CEO
 WEBSITEionispharma.com
 INDUSTRYBiotechnology
 EMPLOYEES796

Ionis Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Ionis Pharmaceuticals Inc? What does IONS stand for in stocks?

IONS is the stock ticker symbol of Ionis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ionis Pharmaceuticals Inc (IONS)?

As of Fri Jul 19 2024, market cap of Ionis Pharmaceuticals Inc is 6.98 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IONS stock?

You can check IONS's fair value in chart for subscribers.

What is the fair value of IONS stock?

You can check IONS's fair value in chart for subscribers. The fair value of Ionis Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ionis Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IONS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ionis Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether IONS is over valued or under valued. Whether Ionis Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Ionis Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IONS.

What is Ionis Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, IONS's PE ratio (Price to Earnings) is -18.15 and Price to Sales (PS) ratio is 8.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IONS PE ratio will change depending on the future growth rate expectations of investors.